Does UnitedHealthcare Cover Belsomra (Suvorexant)?

How UnitedHealthcare Classifies Belsomra on Its Formulary

UnitedHealthcare places Belsomra (suvorexant) on Tier 3 of its commercial formulary. That classification applies across most PPO, HMO, and POS plan designs. Tier 3 means UHC considers Belsomra a "preferred brand" medication, which carries a higher cost-share than Tier 1 generics but remains a covered benefit with appropriate authorization.

Formulary placement can shift between plan years. UHC publishes updated formulary lists each January, and mid-year changes are possible with 60 days' written notice to members 1. For employer-sponsored plans, the specific formulary tier may differ from the standard commercial list because large employers sometimes negotiate custom drug tiers. Your plan's Summary of Benefits and Coverage (SBC) is the definitive document.

Suvorexant is a dual orexin receptor antagonist (DORA) that the FDA approved in August 2014 for insomnia characterized by difficulty with sleep onset and/or sleep maintenance. The approval was based on two key Phase III trials enrolling over 3,000 patients, including a 3-month efficacy study and a 12-month safety study. In the key trial by Herring et al. (Lancet Neurology, 2014; N=1,021), suvorexant significantly reduced time to sleep onset by approximately 8 minutes versus placebo (P<0.001) and increased total sleep time by 16 to 28 minutes across dose groups.

Because newer DORAs like lemborexant (Dayvigo) now compete in the same class, UHC formulary committees weigh comparative pricing when determining preferred status. Belsomra has maintained Tier 3 placement in most recent UHC formulary editions, though members should verify current status through the UHC online formulary tool or by calling the number on the back of their member ID card.

Prior Authorization Requirements for Belsomra

UHC requires prior authorization for Belsomra on virtually all commercial plan types. The PA process is rated as moderate difficulty compared to other specialty or non-preferred drugs. Your prescribing clinician, not you, initiates the request.

The standard PA criteria that UHC applies to Belsomra include three core requirements. First, the patient must have a documented diagnosis of insomnia disorder per DSM-5 criteria. Second, the patient must have tried and failed, or have a documented contraindication to, at least one first-line generic hypnotic. Zolpidem (generic Ambien) and suvorexant's generic DORA alternatives are the most commonly accepted trial agents. Third, the prescriber must confirm the requested dose (10 mg or 20 mg) aligns with FDA labeling, which recommends starting at 10 mg taken no more than once per night, within 30 minutes of bedtime, with at least 7 hours remaining before planned awakening.

Standard PA decisions arrive within 48 to 72 hours. For urgent requests where a delay could seriously jeopardize the patient's health, UHC must render a decision within 24 hours per federal and most state timely-access standards. The American Academy of Sleep Medicine's 2017 clinical practice guideline for insomnia pharmacotherapy lists suvorexant among the recommended agents, which strengthens a PA request when cited by the prescriber.

A helpful clinical strategy: have your prescriber document not just medication failure but the specific reason the generic did not work. "Patient developed complex sleep behaviors on zolpidem 10 mg" carries far more weight with a PA reviewer than "zolpidem ineffective."

Step Therapy: What You Need to Try First

Step therapy is a formal requirement, not a suggestion. UHC's step therapy protocol for Belsomra mandates a trial of at least one preferred generic sleep medication before granting coverage for a branded DORA.

The most commonly accepted step therapy agents on UHC formularies include zolpidem (immediate or extended release), eszopiclone, zaleplon, doxepin 3 mg or 6 mg (Silenor generic), and trazodone. Trazodone is prescribed off-label for insomnia but is frequently accepted by UHC as a valid step therapy trial because of its widespread use and Tier 1 cost profile.

A "failed trial" generally means the patient used the medication for an adequate duration (typically 7 to 14 days at a therapeutic dose) and experienced either insufficient efficacy or intolerable side effects. Documentation should be specific. The AASM 2017 guideline notes that cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment for chronic insomnia, and some UHC plans reference CBT-I engagement as an additional step before pharmacotherapy. This is more common in plans that integrate behavioral health programs.

Patients who have already been stable on Belsomra through a previous insurer may request a step therapy exception. UHC has a continuity-of-care provision for new members transitioning from another plan, which can bypass step therapy if the prescriber submits documentation of prior stable use. This exception typically provides a temporary supply (30 to 90 days) while the formal PA process is completed.

A quick note on generic suvorexant: the first generic versions of suvorexant received FDA tentative approval in 2023, with launch timelines dependent on patent litigation resolution. If a generic becomes available on the UHC formulary, it will likely shift to Tier 1 or Tier 2, potentially eliminating the PA and step therapy requirements entirely.

What You Will Pay Out of Pocket

The math depends on your specific plan design, but Tier 3 drugs on UHC commercial plans typically carry a copay between $35 and $80 for a 30-day supply. Some plans use coinsurance (a percentage of the drug cost) instead of a flat copay, in which case your share could be 25% to 50% of the negotiated price.

Belsomra's wholesale acquisition cost (WAC) from Merck sits near $340 per month for 30 tablets at either the 10 mg or 20 mg strength. The price is the same regardless of dose. Without any insurance, cash-pay pricing through discount card programs like GoodRx or RxSaver typically brings the cost to approximately $85 per month at major chain pharmacies.

For members with a high-deductible health plan (HDHP), the full negotiated cost applies until the deductible is met. On a UHC HDHP, that negotiated rate is usually lower than the $340 list price but higher than the cash-pay discount price. Members should compare their HDHP negotiated rate against cash discount pricing before filling, as it is sometimes cheaper to pay cash and apply a discount card rather than running the claim through insurance pre-deductible.

The Merck Belsomra savings card may reduce the copay to as little as $0 to $15 per fill for commercially insured patients, though it cannot be combined with government insurance (Medicare Part D, Medicaid, TRICARE). Eligibility requires active commercial insurance coverage. The savings card works alongside UHC coverage once the PA is approved.

One caveat: if your plan has an accumulator adjustment program, manufacturer copay assistance may not count toward your annual deductible or out-of-pocket maximum. UHC has increasingly adopted accumulator programs in recent plan years. Check your plan documents or call member services to confirm whether copay card payments apply to your accumulators.

How to Appeal a UnitedHealthcare Denial of Belsomra

A denied PA is not the final answer. UHC provides a two-level internal appeal process followed by an external review through an independent review organization (IRO). Success rates on first-level internal appeals for branded sleep medications run between 40% and 60% when supported by clinical documentation.

Start the first-level appeal within 180 days of the denial notice. Your prescriber should submit a letter of medical necessity that includes the diagnosis, all prior medication trials with specific dates and outcomes, any relevant sleep study data (polysomnography or home sleep test), and a clinical rationale for why suvorexant is medically necessary over available alternatives. Citing the Herring et al. trial data showing statistically significant improvements in subjective total sleep time (sTST) and subjective wake after sleep onset (sWASO) provides quantitative support.

If the first-level internal appeal is denied, a second-level internal appeal goes to a different reviewer who was not involved in the original decision. This is required before proceeding to external review. The second-level decision must be issued within 30 days for standard appeals or 72 hours for expedited appeals.

External IRO review is the final step. The IRO is a third party not affiliated with UHC, and its decision is binding on the insurer in most states. External review can be requested within four months of the final internal denial. According to federal external review regulations under the ACA, the IRO must render a decision within 45 days (72 hours for expedited cases). External reviewers often overturn insurer denials when the clinical documentation is thorough and the prescriber's rationale aligns with published guidelines.

A practical tip: request the complete clinical review file from UHC before filing an appeal. The denial letter includes a summary, but the full file reveals exactly which criteria the reviewer found unmet, allowing the prescriber to target the appeal response precisely.

Clinical Profile: Why Prescribers Choose Suvorexant

Suvorexant works differently from older sleep medications. It blocks orexin receptors, the neuropeptides that promote wakefulness, rather than broadly depressing the central nervous system the way benzodiazepines or Z-drugs do.

The Herring et al. key trial randomized 1,021 patients to suvorexant (40 mg high dose or 20 mg low dose) versus placebo over 3 months. At month 1, the 20 mg dose reduced subjective time to sleep onset by 8.4 minutes more than placebo and increased total sleep time by 22.1 minutes more than placebo. Effect sizes were consistent through month 3. The 12-month safety extension confirmed that suvorexant did not produce rebound insomnia upon discontinuation and showed no evidence of physical dependence at recommended doses [2].

Compared to zolpidem, suvorexant carries a different side effect profile. The most common adverse reactions in clinical trials were somnolence (7% vs. 3% placebo), headache, and dizziness. Complex sleep behaviors (sleepwalking, sleep-driving) have been reported with suvorexant but appear to occur at lower rates than with Z-drugs, based on FDA Adverse Event Reporting System (FAERS) data. The FDA's 2020 boxed warning on complex sleep behaviors applies to all orexin receptor antagonists and Z-drugs equally.

For patients with comorbid conditions, suvorexant offers specific advantages. A post-hoc analysis published in Alzheimer's Research & Therapy (2020) found that suvorexant improved sleep in patients with mild-to-moderate Alzheimer's disease without worsening cognition. That finding is relevant for older adults on UHC Medicare Advantage plans (though coverage criteria differ from commercial plans). The American Geriatrics Society's Beers Criteria lists benzodiazepines and Z-drugs as potentially inappropriate in older adults, making DORAs like suvorexant a preferred pharmacologic option in this population when non-pharmacologic approaches are insufficient.

Belsomra vs. Other Covered Sleep Medications on UHC

UHC's formulary includes several sleep medication options across different tiers. Understanding where each sits helps frame the step therapy sequence and cost implications.

Zolpidem IR and ER (generic) occupy Tier 1 on most UHC plans, with copays typically $3 to $15. Eszopiclone (generic Lunesta) also sits on Tier 1. These are the standard step therapy agents. Doxepin 3 mg and 6 mg (generic Silenor) is Tier 1 as well and is often used for sleep maintenance insomnia specifically.

Lemborexant (Dayvigo), the other branded DORA currently available, typically sits on Tier 3 alongside Belsomra with similar PA requirements. Some UHC plans may prefer one DORA over the other depending on negotiated rebates. The SUNRISE-2 trial compared lemborexant to placebo and showed sleep onset and maintenance improvements comparable in magnitude to suvorexant's trial results, though no head-to-head trial between the two DORAs has been published.

Ramelteon (generic available) targets melatonin receptors and typically sits on Tier 1 or Tier 2 without PA. It is primarily effective for sleep onset rather than maintenance. For patients whose primary complaint is staying asleep rather than falling asleep, suvorexant's dual-action mechanism (improving both onset and maintenance) provides a rationale for the PA request.

Low-dose trazodone (off-label) is the most prescribed sleep medication in the United States, with over 25 million prescriptions annually per IQVIA data. It is Tier 1 and requires no PA. While trazodone lacks FDA approval for insomnia, UHC accepts a trazodone trial as meeting step therapy requirements for Belsomra.

Tips for Getting Belsomra Covered Faster

Preparation shortens the process. Before the prescriber submits the PA, gather documentation of all prior sleep medication trials, including pharmacy records showing fill dates and durations. If you completed a CBT-I program, obtain a summary letter from your therapist. These records eliminate back-and-forth between UHC and the prescriber's office, which is the most common cause of PA delays.

Ask your prescriber to use UHC's electronic PA (ePA) system through their EHR rather than faxing a paper form. Electronic submissions receive faster triage and reduce processing errors. Most major EHR systems (Epic, Cerner, athenahealth) support ePA for UHC plans through the CoverMyMeds platform.

If your plan year is resetting soon, timing matters. A PA approval for Belsomra on UHC commercial plans typically lasts 12 months. If your plan renews in January, submitting the PA in December means you may need to re-authorize just one month later. Aim to align the PA submission with the start of your plan year when possible.

For patients currently paying cash while the PA process is underway, ask your prescriber for a bridge prescription of suvorexant 10 mg (the starting dose) and use a discount card. The cash price of approximately $85 per month covers you during the typical 2 to 5 business day PA review period without a coverage gap.

Confirm your pharmacy is in-network. Out-of-network pharmacies may not process UHC PAs, even if the authorization is approved. UHC's mail-order pharmacy (OptumRx for most commercial plans) often provides the lowest Tier 3 copay for a 90-day supply, sometimes at the cost of two copays rather than three.

The FDA-recommended starting dose is 10 mg nightly, with an option to increase to 20 mg if 10 mg is tolerated but insufficiently effective. Both strengths carry the same list price and the same Tier 3 copay on UHC plans.